by Truveta Research | Jul 24, 2025 | Research
Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
by Truveta staff | Jan 31, 2025 | Research
Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
by Truveta staff | Oct 14, 2024 | Research
Overall prescribing rates for GLP-1 medications increased in September 2024 relative to June 2024 (+11.9%). While the rate of GLP-1 prescriptions labeled for type 2 diabetes were about the same as June 2024 (+4.0%), the rate of prescriptions for GLP-1 medications...
by Truveta Research | Aug 22, 2024 | Research, Research Insights
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
